Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Articles

Page 1 of 8

  1. Neoplasms are a major cause of mortality globally, where early diagnosis is essential for improving outcomes. Current diagnostic methods are often invasive, expensive, and inaccessible in resource-limited sett...

    Authors: Juan Miguel Lopez Alcaraz, Wilhelm Haverkamp and Nils Strodthoff
    Citation: Cardio-Oncology 2025 11:70
    Content type: Research Published on:

  2. A cardio-oncology multidisciplinary team is essential for the successful delivery of patient-centred care. The roles of oncologists, haematologists, and cardiologists have been clearly articulated in literatur...

    Authors: Joshua D. Bennetts, Trent D. Williams, Craig J. Beavers, Heather N. Moore, Cameron Robson, Thomas Warner, Susan Dent, Aaron L. Sverdlov and Doan T.M. Ngo
    Citation: Cardio-Oncology 2025 11:69
    Content type: Review Published on:

  3. Tyrosine kinase inhibitor (TKI) therapy improves the overall survival of patients with chronic myeloid leukemia (CML). However, the risk of vascular adverse events (VAEs) in these patients is reported to be hi...

    Authors: Naoki Watanabe, Tomoiku Takaku, Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomonori Nakazato, Michihide Tokuhira, Hiroyuki Fujita, Miki Ando, Katsuhiro Miura and Tatsuya Kawaguchi
    Citation: Cardio-Oncology 2025 11:68
    Content type: Research Published on:

  4. Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD),...

    Authors: Abdelrahman Ali, Maximillian Bourdillon, Hyeon-Ju Ryoo Ali, Juhee Song, Efstratios Koutroumpakis, Poonam Jewani, Shaden Khalaf, Ihab Hamzeh, Salil Kumar, Nicolas L. Palaskas, Jean-Bernard Durand and Cezar Iliescu
    Citation: Cardio-Oncology 2025 11:67
    Content type: Research Published on:

  6. Anthracycline-induced cardiotoxicity is a significant concern for breast cancer patients undergoing treatment, often leading to chronic cardiovascular complications and reduced long-term survival. The study ai...

    Authors: Runyu Liu, Cong Fan, Xiaoling Liu, Mengmeng Li, Yuan Zhang and Mei Zhang
    Citation: Cardio-Oncology 2025 11:65
    Content type: Review Published on:

  7. The risk of drug-induced corrected QT interval (QTc) prolongation is an important consideration in clinical decision-making for patients with hormone receptor-positive/human epidermal growth factor receptor 2-...

    Authors: Susan Dent, Heather Moore, Michael Fradley, Chloe Grace Rose, Stella Stergiopoulos, Connie Chen, Benjamin Li and Avirup Guha
    Citation: Cardio-Oncology 2025 11:64
    Content type: Research Published on:

  8. Cardiovascular adverse events (CVAE) are clinically relevant side effects during treatment with the proteasome inhibitor carfilzomib. We investigated the predictive value of cardiac biomarkers for onset of CVA...

    Authors: Lisa B. Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-S. Raab, Christoph Mann, Christian S. Michel, Hans Christian Reinhardt, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny…
    Citation: Cardio-Oncology 2025 11:63
    Content type: Research Published on:

  9. Neoadjuvant chemotherapy-immunotherapy is the new standard of care for high-risk early-stage triple negative breast cancer (TNBC). As anthracyclines, pembrolizumab, and radiotherapy may each contribute to an i...

    Authors: Jean Philippe Nesseler, Katrina D. Silos, Olivia Peony, Asneh Singh, Patrick Belen, Mitchell R. Kamrava, Julie K. Jang, Stephen L. Shiao, Alan C. Kwan, Cody Ramin, Raymond H. Mak, Andriana P. Nikolova and Katelyn M. Atkins
    Citation: Cardio-Oncology 2025 11:62
    Content type: Research Published on:

  10. Stem Cell Transplantation (SCT) is a cornerstone therapy in managing several malignant and benign hematological conditions. Atrial fibrillation/atrial flutter (AF) are commonly encountered in patients receivin...

    Authors: Raja Zaghlol, Elena Deych, Nina Manian, Ahmed Altibi and Joshua D. Mitchell
    Citation: Cardio-Oncology 2025 11:61
    Content type: Research Published on:

  11. Chimeric Antigen Receptor (CAR) T-cell therapy (CAR-T) has emerged as a promising treatment for specific hematological malignancies. While some studies suggest an association between CAR-T and atrial fibrillat...

    Authors: Nischit Baral, Nabin R. Karki, Daniel A. Ladin, Raja Zaghlol, Mahmoud Ibrahim, Alexander Rabadi, Tarec K. Elajami, Olivia Mechanic, Arvind Kunadi and Joshua D. Mitchell
    Citation: Cardio-Oncology 2025 11:60
    Content type: Research Published on:

  12. Pegylated liposomal doxorubicin (PLD) and bevacizumab are commonly used to treat platinum-resistant ovarian cancer. While both agents are associated with cardiovascular toxicities, their combined impact on car...

    Authors: Christopher W. Hoeger, Arrush Choudhary, Andrea Nathalie Rosas Diaz, Theresa Pinto, Sarah Smalec, Charles Doladille, Rishi Wadhera, Meghan Shea, Sumanth Khadke, Joe-Elie Salem, Sarju Ganatra and Aarti Asnani
    Citation: Cardio-Oncology 2025 11:59
    Content type: Research Published on:

  13. Primary cardiac sarcomas (PCS) are rare, aggressive malignancies with poor prognosis and limited evidence guiding optimal management. We aimed to evaluate clinical and histopathological parameters in a single-...

    Authors: Anton Burkhard-Meier, Dorit Di Gioia, Vindi Jurinovic, Michael Hoberger, Sinan E. Güler, Michael Völkl, Stefanie Corradini, Aurélie V. Gaasch, Annabel H. S. Alig, Thomas Knösel, Christian Hagl, Christian Schneider, Wulf Sienel, Wolfgang G. Kunz, Caspar Burkhard-Meier, Michael von Bergwelt-Baildon…
    Citation: Cardio-Oncology 2025 11:58
    Content type: Research Published on:

  15. Cardiovascular toxicity concerns have limited the use of anthracyclines and trastuzumab among breast cancer patients with cardiovascular disease (CVD) but evidence on real-world prescribing patterns is scarce....

    Authors: Helena Carreira, Helen Strongman, Maria Feychting, Laila Hubbert, Elham Hedayati, Patrick Bidulka, Anthony Matthews and Krishnan Bhaskaran
    Citation: Cardio-Oncology 2025 11:56
    Content type: Research Published on:

  16. Childhood cancer survivors (CCS) often develop late complications after their primary disease is cured. Cardiovascular disease is one of the most frequent and serious complications that significantly affects p...

    Authors: Yuri Okazoe-Hirakawa, Kimikazu Yakushijin, Keiji Kurata, Sakuya Matsumoto, Hiroya Ichikawa, Rina Sakai, Taku Nose, Shiro Kimbara, Yoshiaki Nagatani, Taiji Koyama, Yumiko Inui, Yohei Funakoshi, Naomi Kiyota, Mitsuhiro Ito, Keiko Hatazawa, Hidekazu Tanaka…
    Citation: Cardio-Oncology 2025 11:55
    Content type: Research Published on:

  17. Breast cancer survivors treated with radiotherapy (RT) face elevated long-term risk of cardiovascular complications. Double product (DP), the product of systolic blood pressure and heart rate, reflects myocard...

    Authors: Juan Manuel Garzon-Dangond, Maria F. Gomez Ardila, Eduardo Tellez Garcia, Andres E. Daryanani, Prema P. Peethambaram, Lori A. Thicke, Daniela L. Stan and Hector R. Villarraga
    Citation: Cardio-Oncology 2025 11:54
    Content type: Research Published on:

  18. Anthracycline-induced cardiotoxicity (ACT) is a significant concern for cancer survivors, while genetic basis of ACT remains unclear. This study employs a murine genetic reference population (GRP) of BXD recom...

    Authors: Buyan-Ochir Orgil, Akhilesh K. Bajpai, Neely Alberson, Morgan Lander, Batsaikhan Enkhzul, Hugo R. Martinez, Jeffrey A. Towbin, Lu Lu and Enkhsaikhan Purevjav
    Citation: Cardio-Oncology 2025 11:53
    Content type: Research Published on:

  19. Non-cancer deaths are now becoming a significant threat to the health of cancer patients. Death from atherosclerosis is linked to cancer due to the side effects of treatment and its pathogenesis. However, guid...

    Authors: Ramez M. Odat, Sakhr Alshwayyat, Dang Nguyen, Tala Abdulsalam Alshwayyat, Hanan M. Qasem, Hritvik Jain, Hamdah Hanifa, Osama Aloudat, John C. Lin, Wilfred Ngwa, Margaret E. G. Thompson and Amer Harky
    Citation: Cardio-Oncology 2025 11:52
    Content type: Research Published on:

  20. Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting. This study investigates the risk of AF asso...

    Authors: Patrick A. Kwaah, Samuel A. Mensah, Emmanuel A. Agyemang, Joseph S. Kekrebesi, Daniil Katkov, Abraham Carboo, Grace Appah, Hamza A. Rashid and Jennifer M. Kwan
    Citation: Cardio-Oncology 2025 11:51
    Content type: Research Published on:

  21. The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on reducing cardiovascular events in different subgroups of diabetic patients are under investigation. The current systematic review and meta-an...

    Authors: Tara Reshadmanesh, Reza Mohebi, Amir Hossein Behnoush, Azadeh Reshadmanesh, Amirmohammad Khalaji, Mitra Norouzi, Elmira Javanmardi, Reza Pishdad, S. Reza Jafarzadeh, Elina Ghondaghsaz and Sandra Chaparro
    Citation: Cardio-Oncology 2025 11:50
    Content type: Review Published on:

  22. Global longitudinal strain (GLS) is an important prognostic indicator for predicting heart failure and cancer therapy-related cardiac dysfunction (CTRCD). Although access to GLS measurement has increased acros...

    Authors: Tagayasu Anzai, Kenji Hirata, Ken Kato and Kohsuke Kudo
    Citation: Cardio-Oncology 2025 11:49
    Content type: Research Published on:

    The Correction to this article has been published in Cardio-Oncology 2025 11:57

  23. Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment...

    Authors: Johanne D. Lyhne, Vibeke B. Hansen, Lone D. Vestergaard, Susanne E. Hosbond, Martin Busk, Mayooran Gnanaganesh, Else Maae, Birgitte M. Havelund, Torben F. Hansen, Signe Timm, Lars H. Jensen and Mads D. Lyhne
    Citation: Cardio-Oncology 2025 11:48
    Content type: Research Published on:

  24. Anthracycline-induced cardiomyopathy is a well-established adverse consequence in childhood cancer survivors. Altered mRNA expression in the peripheral blood has been found at the level of genes and pathways a...

    Authors: Purnima Singh, David K. Crossman, Changde Cheng, Patrick J. Trainor, Noha Sharafeldin, Xuexia Wang, Liting Zhou, Lindsey Hageman, Saro H. Armenian, Frank M. Balis, Douglas S. Hawkins, Frank G. Keller, Melissa M. Hudson, Joseph P. Neglia, Jill P. Ginsberg, Wendy Landier…
    Citation: Cardio-Oncology 2025 11:47
    Content type: Research Published on:

  25. This study aimed to investigate the impact of the proportion of hematologic malignancy patients in hospitals on the prognosis of chronic lymphocytic leukemia (CLL) patients undergoing cardiac surgery. Perioper...

    Authors: Meizhen Yi, Lanxin Hu, Jifang Zhou, Yali Ge, Cunhua Su and Fan Yang
    Citation: Cardio-Oncology 2025 11:46
    Content type: Research Published on:

  26. Cardiac involvement is the primary driver of death in systemic light chain (AL) amyloidosis. However, the early prediction of cardiac death risk in AL amyloidosis remains insufficient.

    Authors: Naidong Pang, Ying Tian, Hongjie Chi, Xiaohong Fu, Xin Li, Shuyu Wang, Feifei Pan, Dongying Wang, Lin Xu, Jingyi Luo, Aijun Liu and XingPeng Liu
    Citation: Cardio-Oncology 2025 11:45
    Content type: Research Published on:

  27. Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protect...

    Authors: Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar and Jacob K. Kresovich
    Citation: Cardio-Oncology 2025 11:44
    Content type: Research Published on:

  28. The emerging discipline of cardio-oncology addresses the cardiovascular complications associated with cancer therapies. In sub-Saharan Africa (SSA), where both cardiovascular disease (CVD) and cancer-related m...

    Authors: Princess Afia Nkrumah-Boateng, Adam Ben-Jaafar, Allswell Naa Adjeley Boye, Pearl Ohenewaa Tenkorang, Toufik Abdul-Rahman and Wireko Andrew Awuah
    Citation: Cardio-Oncology 2025 11:43
    Content type: Correspondence Published on:

  29. Dexrazoxane, a putative iron chelator, is effective in preventing doxorubicin-induced cardiotoxicity. However, dexrazoxane is also a catalytic inhibitor of topoisomerase 2b (Top2b), a key mediator of doxorubic...

    Authors: Hui-Ming Chang, Jinn-Yuan Hsu, Chul Ahn and Edward T. H. Yeh
    Citation: Cardio-Oncology 2025 11:42
    Content type: Research Published on:

  30. Cardiac benign metastatic leiomyoma (BML) is a rare cardiac tumor that is usually asymptomatic, frequently misdiagnosed and may result in serious complications, including embolization, heart failure and death....

    Authors: Pankaj Garg, Mostafa Ali, Mohammad Alomari, J. Kenneth Schoolmeester, Mark Edgar, Carolyn K. Landolfo, Steven Attia and Kevin P. Landolfo
    Citation: Cardio-Oncology 2025 11:41
    Content type: Review Published on:

  31. Cardio-inflammatory immune related adverse events (irAEs) while receiving immune checkpoint inhibitor (ICI) therapy are particularly consequential due to their associations with poorer treatment outcomes. Eval...

    Authors: Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami and Aya F. Ozaki
    Citation: Cardio-Oncology 2025 11:40
    Content type: Research Published on:

  32. Anthracyclines are essential in early breast cancer chemotherapy but pose long-term cardiotoxicity risks.

    Authors: Nattaya Poovorawan, Thiti Susiriwatananont, Chinachote Teerapakpinyo, Pajaree Chariyavilaskul, Piyada Sitthideatphaiboon, Luxica Jarutasnangkul, Monravee Tumkosit, Pairoj Chattranukulchai, Nonthikorn Theerasuwipakorn, Chatchawit Aporntewan, Shanop Shuangshoti, Sopark Manasnayakorn, Chanida Vinayanuwattikun, Yongkasem Vorasettakarnkij and Virote Sriuranpong
    Citation: Cardio-Oncology 2025 11:39
    Content type: Research Published on:

  33. Coronary artery calcification (CAC) scoring can be performed as a by-product of computed tomography (CT). CAC scoring may reflect the general cardiovascular risk profile of patients. The aim of the present stu...

    Authors: Hans-Jonas Meyer, Wolfram Pönisch, Jan Borggrefe and Alexey Surov
    Citation: Cardio-Oncology 2025 11:38
    Content type: Research Published on:

  34. Cardiotoxic, anthracycline-based therapies have high value in selected patients with breast cancer. We aimed to describe the effect of anthracycline plus taxane and single taxane chemotherapies on echocardiogr...

    Authors: Árpád Kézdi, Emese Szelke, Magdolna Dank, Dorottya Mühl, Gyöngyvér Szentmártoni, Gergely Szabó, Dominic Joseph Fogarasi, István Takács, Viktor J Horváth and Ádám G Tabák
    Citation: Cardio-Oncology 2025 11:37
    Content type: Research Published on:

  35. Cardiovascular mortality is a major cause of death in prostate cancer (PCa) survivors, yet tools for cardiovascular risk stratification in this population are lacking. Although hemoglobin A1c (HbA1c) is routin...

    Authors: Adithya K. Yadalam, Alexander C. Razavi, Sagar A. Patel, Chang Liu, Yan V. Sun and Anant Mandawat
    Citation: Cardio-Oncology 2025 11:36
    Content type: Correspondence Published on:

  36. Breast cancer (BC) patients face abnormal lipid metabolism and increased cardiovascular disease (CVD) risk due to endocrine therapies (ETs). This study evaluates CVD incidence and lipid abnormalities in Chines...

    Authors: Cheng Zeng, Hong Li, Wenna Wang, Lixi Li, Binliang Liu, Bo Lan, Qing Li, Wenjing Yang, Jiani Wang and Fei Ma
    Citation: Cardio-Oncology 2025 11:35
    Content type: Research Published on:

  38. Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China.

    Authors: Fu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, Kong-Jia Luo, Shi-Yu Wang, Wei-Hua Meng, Feng Sha, Zhi-Rong Yang, Allan Hackshaw and Jin-Ling Tang
    Citation: Cardio-Oncology 2025 11:33
    Content type: Research Published on:

  39. Cardiotoxicity has become a major concern in cancer patients, especially those with lung cancer, as anti-tumor therapies can significantly affect patient survival and quality of life. This study aims to develo...

    Authors: Yumin Wang, Chunyan Huan, Huijuan Pu, Guodong Wang, Yan Liu, Xiuli Zhang, Chengyang Li, Jie Liu, Wanling Wu and Defeng Pan
    Citation: Cardio-Oncology 2025 11:32
    Content type: Research Published on:

  40. Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated...

    Authors: Nishant P. Shah, Avinash Singh, Tia Higano, Derya Tilki, Neil Fleshner, Paul Nguyen, Chris Plummer, Juan Gomez Rivas, Kathleen Zhang, Ricardo Rendon, Alicia Morgans, Filipe Cirne, Darryl Leong, Daniel Lenihan and Renato D. Lopes
    Citation: Cardio-Oncology 2025 11:31
    Content type: Correspondence Published on:

  41. Myocarditis is a dreaded complication of immune-checkpoint inhibitor (ICI) therapy but challenging to diagnose. There are no published data comparing the two leading diagnostic criteria for ICI-related myocard...

    Authors: Milagros Pereyra Pietri, Juan M. Farina, Isabel G. Scalia, Ahmed K. Mahmoud, Michael Roarke, Beman Wasef, Cecilia Tagle-Cornell, Courtney R. Kenyon, Mohammed Tiseer Abbas, Nima Baba Ali, Kamal A. Awad, Niloofar Javadi, Nadera N. Bismee, Carolyn M. Larsen, Joerg Herrmann, Reza Arsanjani…
    Citation: Cardio-Oncology 2025 11:30
    Content type: Research Published on:

  43. Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of no...

    Authors: Filipe Cirne, Michiel Sedelaar, Vivek Narayan, Ariane Macedo, Christopher Koo, Jeffrey de Jesus, Anthony Ng, Diogo Bastos, Alberto Briganti, Susan F. Dent, Nishant P. Shah, Renato D. Lopes, Daniel J. Lenihan and Darryl P. Leong
    Citation: Cardio-Oncology 2025 11:28
    Content type: Correspondence Published on:

  44. SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compa...

    Authors: Hanne M. Boen, Lobke L. Pype, Konstantinos Papadimitriou, Sevilay Altintas, Laure-Anne Teuwen, Sébastien Anguille, Kirsten Saevels, Anke Verlinden, Leen Delrue, Ward A. Heggermont, Matthias Bosman, Pieter-Jan Guns, Hein Heidbuchel, Caroline M. Van De Heyning, Emeline M. Van Craenenbroeck and Constantijn Franssen
    Citation: Cardio-Oncology 2025 11:27
    Content type: Research Published on:

  45. Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights.

    Authors: Aya F. Ozaki, Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Ali Naqvi, Nareh Nowrouzi, Yoshito Zamami and Pranav M. Patel
    Citation: Cardio-Oncology 2025 11:26
    Content type: Correspondence Published on:

  47. Breast cancer survivors are at increased risk of cardiovascular events due to the cardiotoxic effects of cancer treatment. Exercise participation can lower the risk of various adverse cardiovascular health out...

    Authors: Oliver W.A. Wilson, Kaitlyn M. Wojcik, Camryn M. Cohen, Dalya Kamil, Gisela Butera, Charles E. Matthews, Christina M. Dieli-Conwright and Jinani Jayasekera
    Citation: Cardio-Oncology 2025 11:24
    Content type: Review Published on:

  48. Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has cardioto...

    Authors: Aditi Sharma, Maria E. Fierro, Samuel Governor, Aishwarya Kothare, Stella Pak, Karen Liu, Zuha Alam and Prince Otchere
    Citation: Cardio-Oncology 2025 11:23
    Content type: Research Published on:

  49. Anthracycline induced cardiomyopathy (AIC) is an important complication of cancer management. Recent findings showed that with early identification and intervention, AIC may be fully or partially reversible. E...

    Authors: Zac Forbes, Tegan Dunmall, Amanda Tey, Dominic Culligan and Pasquale L. Fedele
    Citation: Cardio-Oncology 2025 11:22
    Content type: Correspondence Published on:

  50. Cancer and cardiovascular diseases are the leading causes of mortality worldwide, as they share common risk factors and exacerbate cardiovascular outcomes when they coexist. This study aimed to assess the clin...

    Authors: Marta Sabaté-Tormos, Alfredo Bardají, Oscar M Peiró, Anna Carrasquer, German Cediel and Jose Luis Ferreiro
    Citation: Cardio-Oncology 2025 11:21
    Content type: Research Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact
    Journal Impact Factor: 3.2 (2024)    
    5-year Journal Impact Factor: 3.3 (2024)    
    Source Normalized Impact per Paper (SNIP): 0.799 (2024)    
    SCImago Journal Rank (SJR): 0.886 (2024)

    Speed 
    Submission to first editorial decision (median days): 13
    Submission to acceptance (median days): 100

    Usage 2024
    Downloads: 253,129
    Altmetric mentions: 271

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Cardio-Oncology

ISSN: 2057-3804

Contact us